Age-related macular degeneration (AMD) is a progressive eye condition that is characterised by the gradual deterioration of the macula, which is the area of the retina responsible for central vision.

AMD is the most common cause of significant irreversible vision loss among the elderly. In the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2016, GlobalData epidemiologists found that the majority of diagnosed incident cases of AMD occurred in women (65.76%), with 7,400,411 cases, while men accounted for 34.24%, with 3,852,822 cases (as shown in Figure 1). According to the American Medical Macular Degeneration Foundation and the National Institute of Health’s National Eye Institute, women are more susceptible to AMD than men because they live approximately 5% longer than men. As the risk for developing AMD dramatically increases with advancing age, GlobalData epidemiologists expect that the burden attributed to AMD will increase considerably over the next few decades, given the increasing aging population worldwide.

Related Reports

GlobalData (2017). EpiCast Report: Age-Related Macular Degeneration – Epidemiology Forecast to 2026, November 2017, GDHCER170-17

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.